%0 Journal Article %A LEE S. SIMON %A C. VIBEKE STRAND %A MAARTEN BOERS %A PETER M. BROOKS %A DAVID HENRY %A PETER S. TUGWELL %T Observations from the OMERACT Drug Safety Summit, May 2008 %D 2009 %R 10.3899/jrheum.090590 %J The Journal of Rheumatology %P 2110-2113 %V 36 %N 9 %X Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions. %U https://www.jrheum.org/content/jrheum/36/9/2110.full.pdf